Actuate Therapeutics (NASDAQ: ACTU) director awarded 15,000 stock options at $2.42

Rhea-AI Filing Summary

ACTUATE THERAPEUTICS, INC. director Dan Zabrowski received a grant of stock options as part of his compensation. The grant covers 15,000 options for Common Stock at an exercise price of $2.42 per share. These options were granted on May 21, 2026 and will vest in full on the one-year anniversary of the grant date. After this award, he holds 15,000 derivative securities directly, with the options scheduled to expire on May 21, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zabrowski Dan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	15,000	$0.00	--

Holdings After Transaction: Stock Options — 15,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 15,000 options Exercise price: $2.42 per share Post-grant derivative holdings: 15,000 derivative securities +2 more

5 metrics

Options granted 15,000 options Stock options grant on May 21, 2026

Exercise price $2.42 per share Conversion or exercise price of options

Post-grant derivative holdings 15,000 derivative securities Total options held following transaction

Grant date May 21, 2026 Transaction date of option award

Expiration date May 21, 2036 Option expiration date

Key Terms

Stock Options, Grant, award, or other acquisition, Common Stock, vest in full on the anniversary

4 terms

Stock Options financial

"security_title: "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vest in full on the anniversary financial

"Options will vest in full on the anniversary of the grant date."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zabrowski Dan

(Last) (First) (Middle)

C/O ACTUATE THERAPEUTICS, INC.

1751 RIVER RUN, SUITE 400

(Street)

FORT WORTH TEXAS 76107

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACTUATE THERAPEUTICS, INC. [ ACTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$2.42	05/21/2026		A		15,000		(1)	05/21/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. Options will vest in full on the anniversary of the grant date.

	/s/ Paul Lytle, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ACTU (Actuate Therapeutics) director Dan Zabrowski report on this Form 4?

Dan Zabrowski reported receiving a grant of 15,000 stock options for Actuate Therapeutics. These options are a compensation award, not an open-market purchase or sale, and give him the right to buy Common Stock at a fixed exercise price.

How many ACTU stock options were granted to Dan Zabrowski and at what price?

He was granted 15,000 stock options covering Common Stock with an exercise price of $2.42 per share. This price is the cost per share he must pay to exercise the options and acquire the underlying stock in the future.

When do Dan Zabrowski’s ACTU stock options vest and expire?

The options will vest in full on the anniversary of the May 21, 2026 grant date. Once vested, they remain exercisable until their stated expiration date of May 21, 2036, assuming other plan conditions are satisfied.

Is this ACTU Form 4 transaction a purchase or sale of common shares?

This Form 4 shows a grant of stock options, classified as an acquisition, not an open-market buy or sell of common shares. No common stock was bought or sold; only derivative securities were awarded as compensation.

How many derivative securities does Dan Zabrowski hold in ACTU after this option grant?

After the grant, he holds 15,000 derivative securities related to Actuate Therapeutics. These represent stock options for Common Stock rather than currently owned shares, and they become exercisable after vesting on the grant anniversary.